Timing Carotid Stent Clinical Study for the Treatment of Carotid Artery Stenosis(Timing Trial)

Sponsor
Suzhou Zenith Vascular Scitech Co., Ltd. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05574972
Collaborator
Xuanwu Hospital, Beijing (Other)
178
1
2
31.4
5.7

Study Details

Study Description

Brief Summary

Evaluate the safety and efficacy of the Timing Carotid Stent for the treatment of carotid artery stenosis in patients.

Condition or Disease Intervention/Treatment Phase
  • Device: Timing Carotid Stent
  • Device: Carotid Wallstent
N/A

Detailed Description

This is a prospective, randomized, concurrent controlled, multi-center study. Patients with carotid artery stenosis will be assigned to either the Timing Carotid Stent or Carotid Wallstent. Each treated patient will be followed and assessed for 12 months after randomization. The hypothesis to be tested is that the safety and effectiveness of the Timing Carotid Stent is not inferior to the Carotid Wallstent.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
178 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Prospective, Multi-center and Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Timing Carotid Stent for Carotid Artery Stenosis(Timing Trial)
Actual Study Start Date :
Oct 18, 2022
Anticipated Primary Completion Date :
Dec 30, 2024
Anticipated Study Completion Date :
May 30, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Timing Carotid Stent

Device: Timing Carotid Stent
all the participants in this group will be performed with Timing Carotid Stent

Active Comparator: Carotid Wallstent

Device: Carotid Wallstent
all the participants in this group will be performed with Carotid Wallstent

Outcome Measures

Primary Outcome Measures

  1. Number of Participants Who Experienced Major Adverse Events (MAE) at 30 days [30 days]

    MAE defined as any death, stroke, or myocardial infarction through 30 days post-index procedure

Secondary Outcome Measures

  1. Number of Participants Who Achieved Stent Technical Success [Procedural]

    Stent Technical Success defined as successful implantation of a Carotid Stent

  2. Number of Participants Who Achieved Procedure Success [Procedural]

    Number of Participants Who Achieved Procedure Success

  3. Target Lesion Revascularization [30 days]

    Any clinically driven revascularization procedure that is performed to increase the luminal diameter inside or within 5 mm of the previously treated lesion

  4. In-Stent Restenosis [1 year]

    ≥50% diameter stenosis within the stented lesion or within 5 mm proximal or distal to the stent at follow-up evaluation

  5. Ipsilateral ischemic stroke [1 year]

    Any ipsilateral ischemic stroke through 1 year post-index procedure

  6. mRS score change [1 year]

    mRS score change through 1 year post-index procedure

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Aged 18-85 years;

  2. Patient is either symptomatic with carotid stenosis ≥50% OR asymptomatic with carotid stenosis ≥70% ;

  3. Target lesion 3.5- 5.5 mm;

  4. Signed informed consent.

Exclusion Criteria:
  1. Target lesion is not caused by atherosclerotic disease;

  2. Target lesion is located at the opening of the common carotid artery;

  3. Patient has severe lesion calcification that may restrict the full deployment of the carotid

  4. Patient has a total occlusion of the target carotid arteries

  5. Patient has a large number of acute or subacute thrombi and arteriovenous malformations near the target lesion

  6. Patient has a severe stenosis or occlusion in series with target lesions

  7. Patient has known severe carotid stenosis contralateral to the target lesion

  8. Patient need angioplasty in other parts (including intracranial and extracranial) at the same time or within 30 days after procedure

  9. Patient has a symptomatic severe stenosis of other blood vessels (including intracranial and extracranial) except carotid artery

  10. Patient is experiencing (or has experienced) an evolving, acute, or recent disabling stroke or intracranial hemorrhage

  11. Patient has a massive stroke or myocardial infarction

  12. Patient has a intracranial aneurysm

  13. Patient has a coagulation dysfunction or abnormal bleeding, or contraindications to heparin and antiplatelet drugs

  14. Patient has known sensitivity to contrast agent

  15. Patient has a platelet < 90 × 109 / L, severe liver and kidney injury, and severe dysfunction of important organs such as heart, lung, liver and kidney

  16. Patient has a uncontrollable severe hyperemia

  17. Patient has a bradycardia

  18. mRS≥3

  19. Patient has life expectancy of less than one year

  20. Patient is currently enrolled in another investigational study protocol

  21. Females who are pregnant or in lactation

  22. Other conditions not suitable for inclusion judged by the researcher -

Contacts and Locations

Locations

Site City State Country Postal Code
1 Xuanwu Hospital Beijing China

Sponsors and Collaborators

  • Suzhou Zenith Vascular Scitech Co., Ltd.
  • Xuanwu Hospital, Beijing

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Suzhou Zenith Vascular Scitech Co., Ltd.
ClinicalTrials.gov Identifier:
NCT05574972
Other Study ID Numbers:
  • ZTYL202201
First Posted:
Oct 12, 2022
Last Update Posted:
Jan 4, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 4, 2023